Diabetes Drug Shows Unexpected Brain Effects After 60 Years

After six decades of clinical use, a well-known antidiabetic drug has unexpectedly demonstrated effects on brain function, offering new avenues for research and potentially reshaping our understanding of its broader therapeutic properties.

A Historic Diabetes Drug Takes on a New Role

For over six decades, metformin has stood as a fundamental treatment for type 2 diabetes, praised for its capacity to lower blood sugar and its affordability. Yet, despite its longstanding use and trusted safety profile, much about how this medicine truly works remained veiled in uncertainty. Recent research from the Baylor College of Medicine in the United States now points to an unexpected mechanism: metformin’s action may reach far beyond the liver or gut—it appears to intervene directly in the brain.

The Brain Connection: Shifting Paradigms in Diabetes Care

The prevailing wisdom long held that metformin’s primary target was the liver, reducing glucose production there. Some studies had also highlighted effects within the intestine. However, under the leadership of pathophysiologist Makoto Fukuda, scientists questioned whether another key player was being overlooked—the brain. Their attention turned specifically to the ventromedial hypothalamus (VMH), a region thought to play a significant role in regulating metabolism.

In experiments with mice, researchers discovered that metformin travels straight to this neural hub, where it disrupts a protein known as Rap1. When Rap1 was absent from these animals’ brains, metformin failed to reduce blood sugar levels—a result not seen with other diabetes drugs tested in parallel. This strongly suggests that part of metformin’s benefit comes from previously unrecognized central mechanisms.

SF1 Neurons: A Window onto Future Treatments

So which cells are involved? The study singles out SF1 neurons in the VMH as active participants when metformin is administered centrally. This finding opens new therapeutic possibilities. Several factors explain this potential breakthrough:

• Treatments could be designed to more precisely target SF1 neurons.
• This specificity might boost effectiveness while minimizing side effects.
• The approach hints at applications beyond diabetes management.

Toward Tailored Diabetes Therapies?

Of course, translating results from rodents to humans will require careful validation. Nevertheless, if this mechanism holds up outside laboratory conditions, strategies for treating diabetes—and possibly even for combating brain aging or increasing longevity—could be dramatically transformed. As Fukuda himself notes, “This discovery changes how we understand metformin: it operates not only in the liver or intestine but also in the brain.”

These findings appear in Science Advances, pointing toward a future where established medicines such as metformin can be harnessed with newfound precision.